Kurzrock R - Search Results

1

Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors.

Naing A, Reuben JM, Camacho LH, Gao H, Lee BN, Cohen EN, Verschraegen C, Stephen S, Aaron J, Hong D, Wheler J, Kurzrock R. Naing A, et al. Among authors: kurzrock r. J Cancer. 2011 Feb 10;2:81-9. doi: 10.7150/jca.2.81. J Cancer. 2011. PMID: 21326629 Free PMC article.

2

Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia.

Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU. Talpaz M, et al. Among authors: kurzrock r. Cancer. 1992 Jan 15;69(2):410-2. doi: 10.1002/1097-0142(19920115)69:2<410::aid-cncr2820690222>3.0.co;2-v. Cancer. 1992. PMID: 1370212

3

Interferon-stimulated genes in interferon-sensitive and -resistant chronic myelogenous leukemia patients.

Talpaz M, Chernajovsky Y, Troutman-Worden K, Wetzler M, Kantarjian H, Gutterman JU, Kurzrock R. Talpaz M, et al. Among authors: kurzrock r. Cancer Res. 1992 Mar 1;52(5):1087-90. Cancer Res. 1992. PMID: 1737366

4

Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia.

Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M. Schilling PJ, et al. Among authors: kurzrock r. Cancer. 1991 Oct 1;68(7):1536-7. doi: 10.1002/1097-0142(19911001)68:7<1536::aid-cncr2820680713>3.0.co;2-b. Cancer. 1991. PMID: 1893353

5

A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia.

Talpaz M, Kurzrock R, Kantarjian H, Rothberg J, Saks S, Evans L, Gutterman JU. Talpaz M, et al. Among authors: kurzrock r. Cancer. 1991 Nov 15;68(10):2125-30. doi: 10.1002/1097-0142(19911115)68:10<2125::aid-cncr2820681006>3.0.co;2-q. Cancer. 1991. PMID: 1913450 Clinical Trial.

6

Phase I study of multiple dose intramuscularly administered recombinant gamma interferon.

Kurzrock R, Quesada JR, Talpaz M, Hersh EM, Reuben JM, Sherwin SA, Gutterman JU. Kurzrock R, et al. J Clin Oncol. 1986 Jul;4(7):1101-9. doi: 10.1200/JCO.1986.4.7.1101. J Clin Oncol. 1986. PMID: 3088221

7

Leukemia inhibitory factor in long-term adherent layer cultures: increased levels of bioactive protein in leukemia and modulation by IL-4, IL-1 beta, and TNF-alpha.

Wetzler M, Estrov Z, Talpaz M, Kim KJ, Alphonso M, Srinivasan R, Kurzrock R. Wetzler M, et al. Among authors: kurzrock r. Cancer Res. 1994 Apr 1;54(7):1837-42. Cancer Res. 1994. PMID: 8137298

8

Sweet syndrome in patients with solid tumors.

Cohen PR, Holder WR, Tucker SB, Kono S, Kurzrock R. Cohen PR, et al. Among authors: kurzrock r. Cancer. 1993 Nov 1;72(9):2723-31. doi: 10.1002/1097-0142(19931101)72:9<2723::aid-cncr2820720933>3.0.co;2-f. Cancer. 1993. PMID: 8402496 Review.

9

A phase I study of recombinant interferon-beta in patients with advanced malignant disease.

Ravandi F, Estrov Z, Kurzrock R, Breitmeyer JB, Maschek BJ, Talpaz M. Ravandi F, et al. Among authors: kurzrock r. Clin Cancer Res. 1999 Dec;5(12):3990-8. Clin Cancer Res. 1999. PMID: 10632330 Clinical Trial.

10

Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome.

Fayad L, Keating MJ, Reuben JM, O'Brien S, Lee BN, Lerner S, Kurzrock R. Fayad L, et al. Among authors: kurzrock r. Blood. 2001 Jan 1;97(1):256-63. doi: 10.1182/blood.v97.1.256. Blood. 2001. PMID: 11133769 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,011 results

Search Page

Filters